ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1018

The LMX1βR246Q Mutation Induces Podocyte Injury Through Dysregulation of Cholesterol Transport Gene Expression

Session Information

Category: Genetic Diseases of the Kidney

  • 1002 Genetic Diseases of the Kidney: Non-Cystic

Authors

  • Hall, Gentzon, Duke University Medical Center, Durham, North Carolina, United States
  • Ducasa, Gloria Michelle, University of Miami School of Medicine, Miami, Florida, United States
  • Lane, Brandon M., Duke University, Durham, North Carolina, United States
  • Lagas, Maxwell S., University of Arizona, Phoenix, Arizona, United States
  • Kovalik, Maria Eugenia, Duke University, Durham, North Carolina, United States
  • Gregory, Olivia G., Duke University, Durham, North Carolina, United States
  • Wu, Guanghong, Duke University Medical Center, Durham, North Carolina, United States
  • Chryst-Stangl, Megan, Duke University Medical Center, Durham, North Carolina, United States
  • Wang, Liming, Duke University Medical Center, Durham, North Carolina, United States
  • Spurney, Robert F., Duke University Medical Center, Durham, North Carolina, United States
  • Fornoni, Alessia, University of Miami, Miami, Florida, United States
  • Gbadegesin, Rasheed A., Duke University Medical Center, Durham, North Carolina, United States
Background

We previously reported a heterozygous missense mutation of the LIM Homeobox Transcription Factor 1 Beta (LMX1β) as a cause of nail-platella-like renal disease (NPLRD) in two families with hereditary FSGS. Currently, there are no targeted therapies for LMX1βR246Q-induced glomerulopathy. We hypothesized that LMX1βR246Q disrupts the expression of disease-relevant molecular targets within key signaling pathways that may be amenable to pharmacotherapy. To test this hypothesis, we performed an unbiased, whole-transcriptomic analysis in our established LMX1βWT and LMX1βR246Q-overexpressing podocyte lines to uncover potential therapeutic targets.

Methods

We conducted RNA-seq, qPCR, immunoblot, cholesterol efflux assays and apoptosis assays in our established LMX1βWT, LMX1βR246Q- and VIVIT overexpressing podocytes to evaluate the effect of the LMX1βR246Q mutation on cholesterol transport gene expression, cholesterol efflux and viability.

Results

Using RNA-seq, we determined that LMX1βR246Q-overexpressing podocytes express significantly reduced levels of ATP-binding Cassette Transporter Family A1 (ABCA1) and ABCG1 relative to LMX1βWT-overexpressing podocytes. These results were confirmed by qRCR. Protein expression of ABCA1 and ABCG1 was similarly reduced. Consistent with these findings, LMX1βR246Q-overexpressing podocytes displayed significantly increased lipid droplet accumulation, decreased basal and Apo-AI-stimulated cholesterol efflux and increased apoptosis relative to LMX1βWT-overexpressing podocytes. Evaluation of the putative promoter regions for ABCA1 and ABCG1 revealed no LMX1β binding sequences (i.e. FLAT-E or FLAT-F) but did reveal multiple candidate NFAT binding sequences. LMX1βR246Q-overexpressing podocytes displayed decreased NFAT4 expression and ABCA transporter expression was decreased in VIVIT-overexpressing podocytes.

Conclusion

The LMX1βR246Q mutation may cause FSGS, in part, through the dysregulation of NFAT-dependent lipid trafficking gene expression. This study provides the first demonstration of a potential role for impaired lipid trafficking in the pathobiology of familial FSGS and suggests that lipid depleting therapies may have a role in the treatment of some forms of familial FSGS.

Funding

  • NIDDK Support